Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06789757 · ClinicalTrials.gov registry record · Phase 2
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
A Phase 2 study of Hepatocellular Carcinoma, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT06789757: Recruiting Phase 2 study of Hepatocellular Carcinoma, sponsored by Inova Health Care Services.
NCT06789757 is a Phase 2 study of Hepatocellular Carcinoma that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 19 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06789757, a Phase 2 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
Primary Outcome
The effectiveness of the combination therapy using Azozolizumab, Bevacizumab,and Memantine in relation to the Objective Response Rate (ORR), defined as the proportion of complete or partial responses to the treatment by the response evaluation criteria for solid tumors(RECIST) 1.1.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Memantine Hydrochloride
Study Locations (2)
Virginia
- Inova Schar Cancer Institute - Fair Oaks - Fairfax
- Inova Health Care Service - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2028-01-27 |
| Phase | Phase 2 |
What NCT06789757 shows while recruiting
NCT06789757 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06789757 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06789757 about?
NCT06789757 is a clinical study titled "The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)". The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
What is the current status of trial NCT06789757?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2025-02-25. Estimated completion is 2028-01-27.
What conditions does trial NCT06789757 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06789757?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Memantine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06789757?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06789757 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06789757's enrollment target sits among peer trials
19 131st of 145 higher than 15 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI